Bio Vitos Pharma AB (publ) ("Bio Vitos") has entered into a liquidity provider agreement with Lago Kapital ("LAGO").
According to the agreement, LAGO undertakes to continuously quote prices on both the buy- and sell side for Bio Vitos share in accordance with the framework of Nasdaq Stockholm's rules for liquidity provision. The purpose is to promote liquidity and reduce spread and volatility of the share. LAGO's assignment commences on 15th of november 2024.
For further information, contact:
Bio Vitos Pharma AB (publ)
Jesper Birgemo, CEO
Tel: +46 (0) 70 895 39 34
About Bio Vitos Pharma AB
Bio Vitos Pharma develops, produces and commercializes iron succinate for the treatment of iron deficiency.
The company is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB is Certified Adviser to the company.